ArticleTumori2026
Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.
Article in Tumori, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aimThere is limited data on the safety of switching between CDK4/6i to address toxicity-related permanent discontinuation in patients with HR+/HER2- advanced breast cancer (ABC).To overcome this issue, this international observational study included consecutive HR+/HER2- ABC patients treated with CDK4/6i at two cancer centers, who switched the CDK4/6i for toxicity. The study aimed to evaluate the safety, feasibility, and clinical impact of this approach.ResultsAmong 1413 patients, 67 (4.5%) switched CDK4/6i due to toxicity. The median time to switch was three months. Adverse events leading to switch were mainly hematologic and hepatic. Recurrence of the same toxicity occurred in 30% of patients, but with lower severity for neutropenia (p=0.047) and hepatotoxicity (p=0.005). Notably, among the 67 patients who switched CDK4/6i, only seven (10%) ultimately required permanent discontinuation of the second CDK4/6i for toxicity, primarily for abemaciclib-induced diarrhea, suggesting that switching may represent a promising strategy to avoid treatment interruption. Median progression-free survival from the start of the first CDK4/6i was 16.8 monthsConclusionIn conclusion, switching CDK4/6i appears to be a safe and pragmatic strategy to address toxicity-related permanent discontinuation of CDK4/6i.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.